ScienceDaily (Oct. 23, 2006) — Montréal scientists led by Dr Jacques Drouin, researcher at the Institut de recherches cliniques de Montréal (IRCM), and collaborators from around the world (Canada, France, the Netherlands and United States) unravel mechanism of hormone resistance in pituitary tumors of Cushing disease patients.

Cushing disease is caused by pituitary tumors that produce excessive amounts of hormone because the tumor cells have become resistant to negative feedback control by a class of steroid hormones, glucocorticoids. In Cushing disease, this excessive hormone production can lead to hypertension, obesity, diabetes and osteoporosis. Through detailed molecular investigation of the mechanism of this negative feedback, a Montréal research group has identified two essential components (proteins) of this feedback mechanism. Extrapolating from these basic studies, they have shown that about half of the pituitary tumors from Cushing disease patients are deficient in expression of either of these proteins, thus providing a molecular explanation for the hormone resistance that is the hallmark, and likely first event, in the formation of these tumors. The novel insight provided by knowledge of the basic mechanism of hormone resistance will lead to the rational design of therapeutic approaches for the better management of Cushing disease patients. This insight will also help understand other forms of hormone resistant cancers.

Dr. Jacques Drouin is the Director of the Molecular Genetics Research Unit at IRCM. He holds the GlaxoSmithKline Chair in Molecular Genetics. The IRCM (http://www.ircm.qc.ca) is recognized as one of the country's top-performing research centres. It has a mandate to establish links between research and patients, promote the prevention of illness, and train a new generation of high-level scientists. The IRCM has 37 research units and a staff of more than 450. The IRCM is also affiliated to Université de Montréal.

This work is published in Genes and Development (Bilodeau et al, Genes Dev 2006, 20:2871-2886) and it was supported by grants from the Canadian Cancer Society and from the Canadian Institutes of Health Research.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Institut de recherches cliniques de Montréal.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Related Stories

New Model Taps Tiny, Common Tropical Fish for Large-Scale Drug Screening to Combat Cushing Disease (May 9, 2011) — A common, tiny tropical fish plays a key role in a new model for Cushing disease, giving researchers a powerful tool to conduct extensive searches for effective treatments for this serious hormonal ...  > read more

Patients With Mild Cushing Syndrome May Benefit From Adrenalectomy (Dec. 10, 2007) — Patients with a mild form of Cushing syndrome, a metabolic disorder caused by adrenal tumors, showed substantial clinical improvement after adrenalectomy. The study is the largest series of surgical ...  > read more

Unexpected Discovery On Hormone Secretion (July 28, 2011) — Geneticists have made an unexpected discovery on hormone secretion. Contrary to common belief, the researchers found that pituitary cells are organized in structured ...  > read more

Tumor 'Stem-Like Cells' Exist In Benign Tumors (July 28, 2009) — Cancer stem-like cells have been implicated in the genesis of a variety of malignant cancers. Research scientists have now isolated stem-like cells in benign (pituitary) tumors and used these ...  > read more

Search ScienceDaily